

# Adrian Gheorghe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2642500/publications.pdf>

Version: 2024-02-01

28  
papers

1,578  
citations

471509

17  
h-index

526287

27  
g-index

28  
all docs

28  
docs citations

28  
times ranked

3272  
citing authors

#	ARTICLE	IF	CITATIONS
1	The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health, 2018, 18, 975.	2.9	268
2	Impact of wound edge protection devices on surgical site infection after laparotomy: multicentre randomised controlled trial (ROSSINI Trial). BMJ, The, 2013, 347, f4305-f4305.	6.0	204
3	Action to address the household economic burden of non-communicable diseases. Lancet, The, 2018, 391, 2047-2058.	13.7	170
4	Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15520-15525.	7.1	153
5	The path to longer and healthier lives for all Africans by 2030: the Lancet Commission on the future of health in sub-Saharan Africa. Lancet, The, 2017, 390, 2803-2859.	13.7	150
6	Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers. PLoS ONE, 2014, 9, e110216.	2.5	73
7	HTA Implementation Roadmap in Central and Eastern European Countries. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Over 1.7 62		
8	Systematic Review of the Clinical Effectiveness of Wound-edge Protection Devices in Reducing Surgical Site Infection in Patients Undergoing Open Abdominal Surgery. Annals of Surgery, 2012, 255, 1017-1029.	4.2	61
9	Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols. PLoS ONE, 2014, 9, e110229.	2.5	58
10	Health Utility Values Associated with Surgical Site Infection: A Systematic Review. Value in Health, 2015, 18, 1126-1137.	0.3	56
11	Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK. European Journal of Cancer, 2021, 152, 233-242.	2.8	48
12	Patient reported outcome assessment must be inclusive and equitable. Nature Medicine, 2022, 28, 1120-1124.	30.7	47
13	The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review. Value in Health, 2022, 25, 385-389.	0.3	44
14	The economic burden of stroke: a systematic review of cost of illness studies. Journal of Medicine and Life, 2021, 14, 606-619.	1.3	39
15	Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study. The Lancet Global Health, 2020, 8, e1071-e1080.	6.3	32
16	The economic burden of cancer care for Syrian refugees: a population-based modelling study. Lancet Oncology, The, 2020, 21, 637-644.	10.7	30
17	Centre Selection for Clinical Trials and the Generalisability of Results: A Mixed Methods Study. PLoS ONE, 2013, 8, e56560.	2.5	24
18	Healthcare Costs and Life-years Gained From Treatments Within the Advancing Cryptococcal Meningitis Treatment for Africa (ACTA) Trial on Cryptococcal Meningitis: A Comparison of Antifungal Induction Strategies in Sub-Saharan Africa. Clinical Infectious Diseases, 2019, 69, 588-595.	5.8	18

#	ARTICLE	IF	CITATIONS
19	Opportunities and challenges for implementing cost accounting systems in the Kenyan health system. <i>Global Health Action</i> , 2016, 9, 30621.	1.9	15
20	Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index. <i>Pharmacoeconomics</i> , 2015, 33, 1195-1214.	3.3	7
21	Assessing the feasibility and appropriateness of introducing a national health insurance scheme in Malawi. <i>Global Health Research and Policy</i> , 2019, 4, 13.	3.6	6
22	Rational Centre Selection for RCTs with a Parallel Economic Evaluation-the Next Step Towards Increased Generalisability?. <i>Health Economics (United Kingdom)</i> , 2015, 24, 498-504.	1.7	3
23	Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development. <i>Health Research Policy and Systems</i> , 2020, 18, 99.	2.8	3
24	A systematic examination of international funding flows for Ebola virus and Zika virus outbreaks 2014-2019: donors, recipients and funding purposes. <i>BMJ Global Health</i> , 2021, 6, e003923.	4.7	3
25	The need for increased harmonisation of clinical trials and economic evaluations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 171-173.	1.4	2
26	How concentrated are academic publications of countries' progression towards universal health coverage?. <i>The Lancet Global Health</i> , 2019, 7, e696-e697.	6.3	1
27	Delivering reproductive health services through non-state providers in Pakistan: understanding the value for money of different approaches. <i>Global Health Research and Policy</i> , 2018, 3, 33.	3.6	1
28	The global scale and implications of delivering multiple interventions through integrated child health events. <i>BMJ Global Health</i> , 2019, 4, e001333.	4.7	0